Protocol Ledger

NCT06439342 · Phase III · COMPLETED

A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections

Interventional Phase III clinical trial protocol NCT06439342 sponsored by Takeda in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-16 Enrollment: 20 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06439342
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)20 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06439342
Protocol FieldVerified Registry Value
NCT IdentifierNCT06439342
Consolidated Lead SponsorTakeda
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment20 participants (ACTUAL)
Registered Start Date2024-12-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI